Skip to main content

Merck & Co., Inc. company profile

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$143.16−0.90%Close 17 Nov 2026 · Market value $354.8B

About Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global health care company that develops and markets prescription medicines, including biologic therapies, vaccines and animal health products. It operates two reportable segments. The Pharmaceutical segment offers human health therapeutic and preventive agents, generally sold by prescription, and pediatric, adolescent and adult vaccines, selling primarily to drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians and distributors. The Animal Health segment offers veterinary pharmaceutical and vaccine products, health management solutions and digitally connected identification and traceability products for livestock and companion animals, selling to veterinarians, distributors, animal producers, farmers and pet owners. The Company's products are sold in markets across the world.

A summary of the business section of the company's latest annual report, filed 24 Feb 2026.

Company facts

TickerMRK · NYSE
SectorPharmaceuticals
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK310158
Latest annual report10-K, filed 24 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Robert M. DavisChairman, CEO & President · Director1.2M · < 1%Shares withheld for tax, 29 Apr 2026
Sanat ChattopadhyayExe V-P & Pres. MMD573K · < 1%Option exercise, 29 Apr 2026
Dean LiExecutive VP & President, MRL405K · < 1%Option exercise, 29 Apr 2026
Caroline LitchfieldEVP & CFO378K · < 1%Shares withheld for tax, 29 Apr 2026
Jennifer ZacharyEVP, General Counsel125K · < 1%Option exercise, 12 Aug 2026
Inge G. ThulinDirector28.4K · < 1%Open-market purchase, 6 Feb 2025
Douglas M. Baker, Jr.Director25.6K · < 1%Open-market purchase, 5 Feb 2025
DeLuca Richard R.EVP&amp;Pres, Merck Animal Heallth—Option exercise, 12 Nov 2026
Guindo ChirfiEVP, Access, Policy & Comms—Open-market sale, 13 Aug 2026
Maraldo David R.EVP & Pres. MMD—Option exercise, 5 Aug 2026
Williams David MichaelEVP,Chief Info&Digital Officer—Option exercise, 5 Aug 2026
Smart Dalton E. IIISVP Fin. - Global Controller—Option exercise, 2 May 2026
Larson Betty DEVP, Chief HR Officer—Option exercise, 30 Apr 2026
Oosthuizen Johannes JacobusEVP, Oncology & Int?l—Shares withheld for tax, 29 Apr 2026
Romanelli JosephPresident, Human Health Int?l—Grant or award, 26 Jan 2026
Downing Cristal NChief Comm. & Public Afrs Ofcr—Open-market sale, 10 Nov 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

MRK in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.